Navigation Links
What Patients Need to Know about Acetaminophen
Date:11/12/2012

BOSTON, Nov. 12, 2012 /PRNewswire/ -- The misuse of acetaminophen is the leading cause of acute liver failure in the West. Informed patients and clearly labeled prescription bottles are necessary to avoid accidental overdoses. Patients with new prescriptions often are unaware of the presence of acetaminophen in their new drug nor do they recall their prescribers' advice concerning acetaminophen, according to researchers at Northwestern University who examined the behavior of 249 patients who were either discharged from a hospital emergency room or recently visited an outpatient pharmacy.

Only 25.7 percent of patients could recall counseling concerning acetaminophen from their prescribers. According to Dr. Marina Serper of The Health Literacy and Learning Program at Northwestern University, "When prescribing an acetaminophen-containing medication, healthcare providers should clearly state the active ingredients in the medication. Providers should explain what constitutes the daily maximum dose of this medication and how it may or may not be combined with other common over the counter acetaminophen preparations."

Researchers asked patients to keep a diary of the medications they had taken in the first seven days after starting their new prescription. All patients were interviewed after seven days to determine the presence of warning labels on bottles, the total amount and sources of acetaminophen taken, patients' knowledge of active ingredients in prescriptions, and patient recall of any communication concerning acetaminophen with the prescriber.

The study also addressed what Dr. Serper refers to as, "the lack of uniformity of prescription labeling." Only 26.9 percent of patients studied correctly identified acetaminophen as an ingredient in their prescription medication. Researchers reported 10.8 percent of those patients studied "double-dipped," meaning that they took their new prescription along with another product containing acetaminophen on the same day – most often an over the counter pain medication.

Four of the 249 patients (1.6 percent) exceeded the recommended daily dose of 4 grams. "In our anecdotal experience, patients do not always understand the meaning of 4000 mg or 4 g and it is more helpful to say something like, 'you should not take more than 8 pills of this medication per day," said Dr. Serper.

Compounding the confusion was that acetaminophen was identified by one of two abbreviations (APAP or ACET) on the prescription label 87.3 percent of the time, and only 59 percent of those prescription bottles had an acetaminophen warning. Dr. Serper addressed this point, "It is equally and perhaps more important to have clear and universal labeling of acetaminophen on prescription bottles, something which does not routinely occur, as shown by our study."

The general confusion faced by patients who are unaware of the active ingredients in their prescription medication because of insufficient or inconsistent labeling of ingredients and warnings, as well as insufficient counseling by prescribers, can put patients in danger of exceeding the daily recommended dose of acetaminophen which can lead to acute liver failure. Researchers concluded that the elimination of abbreviations on prescription labels and more consistent verbal counseling from healthcare providers was needed to minimize this danger.

Abstract title:

Active Ingredient Confusion for Acetaminophen-Containing Medications: A Cause of Double Dipping

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in Boston, Massachusetts November 9 – 13, will bring together more than 9,000 researchers from 55 countries.

A pressroom will be available from November 10 at the annual meeting. For copies of abstracts and press releases, or to arrange researcher interviews, contact Gregory Bologna at 703-299-9766. Press releases and all abstracts are available online at www.aasld.org. Media Contact: Gregory Bologna703/299-9766gbologna@aasld.org Press Room: November 10 – 13, 2012Hynes Convention Center, Boston, MATelephone: 617-954-2624Researcher: Marina Serper, MDEmail: marina-serper@fsm.northwestern.edu Phone: 312-503-3193  This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit http://www.XpressPress.com.


'/>"/>
SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Phreesia identifies over 26% of patients who require additional autism evaluation
4. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
5. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
6. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
7. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
8. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
9. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
Breaking Medicine News(10 mins):